Pancreatic Cancer Breakthrough: FDA Approves Drug After Survival Nearly Doubles in Landmark Trial

The Pancreatic Cancer Breakthrough

A Cancer Once Called ‘Undruggable’ Has Been Hit.

A major new treatment for one of the deadliest forms of cancer has been approved in the United States after a landmark clinical trial found patients receiving the drug lived for a median 13.2 months — almost twice the 6.7 months recorded among those receiving standard chemotherapy. The US Food and Drug Administration approved Rasonque, also known as daraxonrasib, on Wednesday for certain adults with metastatic pancreatic adenocarcinoma.

The significance goes far beyond another drug entering the cancer market. Daraxonrasib attacks the RAS signalling machinery that drives the overwhelming majority of pancreatic ductal adenocarcinomas, confronting a biological target that researchers spent decades struggling to turn into a practical treatment strategy. The Phase 3 results showed a hazard ratio for death of 0.40, corresponding to a 60% reduction in the instantaneous risk of death during the study period compared with chemotherapy.

Survival Nearly Doubled in the Landmark Trial

The approval rests on RASolute 302, an international, randomised, open-label Phase 3 study involving 500 people with previously treated metastatic pancreatic ductal adenocarcinoma. Patients were randomly assigned to receive daraxonrasib or an investigator-selected standard chemotherapy regimen.

Median overall survival across the trial population reached 13.2 months with daraxonrasib compared with 6.7 months for chemotherapy. Among patients whose cancers carried RAS G12 mutations, median survival was also 13.2 months with the drug compared with 6.6 months in the chemotherapy group.

The difference was not confined to overall survival. Median progression-free survival — the time before the disease worsened or the patient died — reached 7.2 months with daraxonrasib compared with 3.6 months in the overall chemotherapy population. In patients with RAS G12 mutations, the figures were 7.3 months and 3.5 months respectively.

These figures do not mean every patient taking Rasonque will live 13 months, nor that the treatment cures metastatic pancreatic cancer. Median survival is the point at which half the patients in a group remain alive, and individual outcomes can vary substantially. But in a disease where progress after previous treatment has historically been painfully limited, the size of the difference is clinically important.

Why This Cancer Has Been So Difficult to Treat

Pancreatic cancer remains unusually lethal relative to how frequently it is diagnosed. US estimates for 2026 project around 67,530 new pancreatic cancer cases and 52,740 deaths, while the five-year relative survival rate across pancreatic cancers remains just 13.7%.

Pancreatic adenocarcinoma accounts for roughly 90% to 95% of pancreatic cancer cases. It is often detected after the disease has already spread, partly because early disease can produce few obvious symptoms and because of the pancreas's position deep within the abdomen.

That combination — aggressive biology, late diagnosis and limited treatment choices after first-line therapy fails — is what makes this approval unusually significant.

Rather than functioning as another conventional chemotherapy, daraxonrasib is an oral targeted drug designed to inhibit active RAS proteins. More than 90% of pancreatic ductal adenocarcinomas contain oncogenic RAS mutations, making the pathway central to the disease's biology.

The Target Scientists Struggled to Drug

RAS has long represented one of cancer biology's most important targets. Mutated forms of the protein can effectively lock cellular growth signals into an active state, allowing malignant cells to continue proliferating.

The problem was finding a drug capable of interfering with that machinery effectively enough to change patient outcomes.

Daraxonrasib is described as a RAS(ON) multiselective inhibitor. Instead of targeting only one narrow mutation, it is designed to inhibit multiple forms of RAS while the protein is in its active state. The FDA said the once-daily tablet targets multiple forms of the protein responsible for driving tumour growth in most people with pancreatic adenocarcinoma.

That mechanism helps explain why the approval could matter outside the immediate group of patients now eligible to receive the drug. If the broader strategy of suppressing active RAS proves effective across additional disease stages or tumour types, the scientific implications could extend far beyond pancreatic cancer.

The FDA Moved Months Ahead of Schedule

The speed of the regulatory decision adds another unusual element to the story.

Daraxonrasib had already received Breakthrough Therapy and Orphan Drug designations as well as Priority Review. It was also reviewed through the FDA Commissioner's National Priority Voucher programme.

The FDA said the approval came 6.5 months before the regulatory user-fee deadline, an exceptionally rapid timetable for a major new oncology therapy. The agency had already allowed an expanded-access programme in May, enabling eligible patients with previously treated metastatic disease to receive daraxonrasib while the formal approval process continued.

The final indication covers adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic treatment or who are not candidates for multiagent systemic therapy. That distinction matters: this is not currently a blanket approval for everybody newly diagnosed with pancreatic cancer.

The Safety Results Matter Too

A major survival gain would be less transformative if it came with an extreme toxicity penalty. The trial therefore produced another important finding.

Grade 3 or more severe adverse events occurred in 61.8% of patients receiving daraxonrasib compared with 69.6% receiving chemotherapy. Treatment-related adverse events caused 1.2% of daraxonrasib patients to discontinue treatment, versus 11.2% among patients receiving chemotherapy.

That does not make the drug side-effect free. The FDA lists common adverse reactions including rash, diarrhoea, stomatitis, nausea, fatigue, vomiting, abdominal pain, oedema, reduced appetite and haemorrhage.

Doctors will therefore still have to balance efficacy, side effects, individual patient health and previous treatment history. But an oral targeted treatment capable of producing a large survival improvement while showing fewer high-grade adverse events than the chemotherapy comparison arm represents an important change in the treatment landscape.

Why This Approval Could Be Bigger Than One Drug

The immediate story is straightforward: patients with previously treated metastatic pancreatic adenocarcinoma now have a new FDA-approved treatment backed by a large randomised Phase 3 survival benefit.

The deeper story is the target.

RAS abnormalities are among the fundamental molecular drivers of cancer, and the RASolute 302 population was overwhelmingly dominated by patients with RAS mutations. Of the 500 people enrolled, 91.8% had RAS G12 mutations.

A drug capable of inhibiting multiple active forms of RAS therefore raises the possibility of a much larger therapeutic platform. Research will now determine how well the approach works earlier in pancreatic cancer treatment and whether similar strategies can deliver meaningful benefits against other RAS-driven malignancies.

That potential should not be confused with what has actually been approved. The evidence supporting Wednesday's decision concerns a defined metastatic pancreatic cancer population, primarily after previous systemic treatment. Results in earlier-stage disease, first-line treatment and other cancers require their own clinical evidence.

What Happens Next

The immediate question is how quickly Rasonque reaches eligible patients and how oncologists incorporate it into routine care. The approval establishes its place as an option after previous therapy and for patients unable to receive multiagent systemic treatment, but real-world experience will now begin to reveal how closely everyday outcomes resemble those seen in the clinical trial.

Longer follow-up will also matter. RASolute 302 remains listed as active but no longer recruiting, with continuing study follow-up, meaning additional survival and safety information can continue to accumulate.

There is still no reason to describe pancreatic cancer as solved. More than 52,000 Americans are expected to die from pancreatic cancer in 2026 alone, and even the 13.2-month median survival achieved in this study shows how devastating metastatic disease remains.

But progress in pancreatic cancer is judged against one of the hardest records in oncology. A once-daily targeted drug has now beaten standard chemotherapy in a 500-patient randomised trial, nearly doubled median overall survival and reduced the hazard of death by 60%. For patients who have spent decades waiting for treatments capable of moving those numbers decisively, the FDA's decision marks a genuine turning point — and perhaps the beginning of a much larger assault on RAS-driven cancer.